Literature DB >> 18677126

The interaction of radiation therapy and antiangiogenic therapy.

Michael S O'Reilly1.   

Abstract

Since its beginning in the early 1970s, the field of angiogenesis research has grown rapidly and it has now become apparent that the endothelial cell is a critical regulator of the malignant phenotype. Multiple antiangiogenic agents have now been used in the clinic yet a better understanding of the process of angiogenesis is still needed before these agents can be successfully incorporated into clinical practice. Although antiangiogenic agents offer great therapeutic potential, preclinical and clinical studies suggest that these agents will have a delayed onset of activity and may only induce disease stabilization for patients with advanced malignancy. The use of radiation therapy for cancer is also associated with therapeutic challenges that are distinct from those that might be expected with antiangiogenic agents. Thus, the use of angiogenesis inhibitors in combination with radiation therapy should help to overcome the limitations of each leading to enhanced efficacy and diminished toxicity. The goal of this review is to provide an update of ongoing progress and current challenges related to the use of angiogenesis inhibitors with radiation therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18677126     DOI: 10.1097/PPO.0b013e3181836af3

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  4 in total

1.  Early postoperative epidermal growth factor receptor inhibition: safety and effectiveness in inhibiting microscopic residual of oral squamous cell carcinoma in vivo.

Authors:  Daisuke Sano; Maria K Gule; David I Rosenthal; Diana Bell; Jeremy Yates; Adel K El-Naggar; Jeffrey N Myers
Journal:  Head Neck       Date:  2012-02-24       Impact factor: 3.147

2.  Angiogenesis inhibitors in the treatment of non-small cell lung cancer.

Authors:  Joline S W Lind; Egbert F Smit
Journal:  Ther Adv Med Oncol       Date:  2009-09       Impact factor: 8.168

3.  Early postoperative paclitaxel followed by concurrent paclitaxel and cisplatin with radiation therapy for patients with resected high-risk head and neck squamous cell carcinoma: report of the phase II trial RTOG 0024.

Authors:  David I Rosenthal; Jonathan Harris; Arlene A Forastiere; Randal S Weber; John A Ridge; Jeffrey N Myers; Adam S Garden; Michael R Kuettel; Kulbir Sidhu; Christopher J Schultz; Andy Trotti; K Kian Ang
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

4.  Two cases of gastrointestinal perforation after radiotherapy in patients receiving tyrosine kinase inhibitor for advanced renal cell carcinoma.

Authors:  Takaaki Inoue; Hidefumi Kinoshita; Yoshihiro Komai; Takashi Kawabata; Gen Kawa; Yoshiko Uemura; Tadashi Matsuda
Journal:  World J Surg Oncol       Date:  2012-08-20       Impact factor: 2.754

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.